Barclays Starts Moderna, Inc. (MRNA) Neutral as Biotech Outlook Improves
On January 28, Barclays assumed coverage of Moderna, Inc. (NASDAQ:MRNA) with an Equal Weight rating and a $25 price target as part of a broader biotechnology coverage expansion.







